PDA-Based Drug Delivery Nanosystems: A Potential Approach for Glioma Treatment
Hao Wu,Min Wei,Yu Xu,Yuping Li,Xue Zhai,Peng Su,Qiang Ma,Hengzhu Zhang
DOI: https://doi.org/10.2147/ijn.s378217
IF: 7.033
2022-08-30
International Journal of Nanomedicine
Abstract:Hao Wu, 1 Min Wei, 1 Yu Xu, 2 Yuping Li, 3 Xue Zhai, 4 Peng Su, 4 Qiang Ma, 3 Hengzhu Zhang 3 1 Neurosurgery, Graduate School of Dalian Medical University, Dalian, People's Republic of China; 2 Nanotechnology, Jinling Institute of Technology, Nanjing, People's Republic of China; 3 Department of Neurosurgery, Clinical Medical College, Yangzhou University, Yangzhou, People's Republic of China; 4 Department of Advanced Materials, Nanjing University of Posts & Telecommunications, Nanjing, People's Republic of China Correspondence: Hengzhu Zhang, 98 Nantong Xi Lu, Yangzhou, Jiangsu Province, People's Republic of China, Tel +86 18051061558, Fax +86-0514-87373562, Email Glioma is characterized by high mortality and low postoperative survival. Despite the availability of various therapeutic approaches and molecular typing, the treatment failure rate and the recurrence rate of glioma remain high. Given the limitations of existing therapeutic tools, nanotechnology has emerged as an alternative treatment option. Nanoparticles, such as polydopamine (PDA)-based nanoparticles, are embodied with reliable biodegradability, efficient drug loading rate, relatively low toxicity, considerable biocompatibility, excellent adhesion properties, precisely targeted delivery, and strong photothermal conversion properties. Therefore, they can further enhance the therapeutic effects in patients with glioma. Moreover, polydopamine contains pyrocatechol, amino and carboxyl groups, active double bonds, catechol, and other reactive groups that can react with biofunctional molecules containing amino, aldehyde, or sulfhydryl groups (main including, self-polymerization, non-covalent self-assembly, π-π stacking, electrostatic attraction interaction, chelation, coating and covalent co-assembly), which form a reversible dynamic covalent Schiff base bond that is extremely sensitive to pH values. Meanwhile, PDA has excellent adhesion capability that can be further functionally modified. Consequently, the aim of this review is to summarize the application of PDA-based NPs in glioma and to acquire insight into the therapeutic effect of the drug-loaded PDA-based nanocarriers (PDA NPs). A wealthy understanding and argument of these sides is anticipated to afford a better approach to develop more reasonable and valid PDA-based cancer nano-dru g delivery systems. Finally, we discuss the expectation for the prospective application of PDA in this sphere and some individual viewpoints. Keywords: glioma, polydopamine, polymeric nanoparticles, photothermal therapy, chemotherapy, synergistic therapy In clinical practice, glioma especially GBM, is known as a malignant tumor originating from glioma cells. This type of tumor has been categorized as a grade IV tumor by the World Health Organization (WHO). 1 The global incidence of primary craniocerebral malignancy has been increasing annually. According to the recent data from The Central Brain Tumour Registry of the United States (CBTRUS), the highest proportion and the most common malignancy among the primary malignancies of the central nervous system (CNS) are attributed to glioma, which accounts for 14.9% of all major craniocerebral malignancies and other CNS tumors, and 47.1% of major malignant brain cancers. Glioma is more common in the elderly population than in children and young adults. The data also suggest that glioma accounts for about 3% of all brain tumors and other CNS tumors reported in patients aged 0–19 years. A positive dynamic distribution of prevalence with increasing age was also confirmed, with the highest prevalence in patients aged 75–84 years and a male-to-female prevalence ratio of 1.58:1. However, 5.5% of patients with glioma have a relative survival rate of <5 years, 2 In addition, the disease rapidly deteriorates with a survival rate of 12–15 months after diagnosis. 3 According to data from the CBTRUS, glioma seriously threatens human health because of its low cure rate and high mortality rate. At present, surgical resection functions as the main treatment modality, however, achieving complete tumor resection is difficult because of its unique anatomical location. Postoperative radiotherapy is the standard strategy for glioma treatment, 4 but clinical evidence shows that although active, when standardized and real-time postoperative radiotherapy is initiated, the benefit for patients is not ideal because of various individual conditions. Temozolomide (TMZ), a first-line United States Food and Drug Administration (USFDA)-approved clinical therapeutic for glioma, can be administered orally or intravenouslyTMZ is currently the primary treatment strategy and it cures tumors by inducing apoptosis. 5 -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology